Table. Descriptive Characteristics of Patients With SJS and TEN Associated With Enfortumab Vedotin.
| Characteristic | No. (n = 8) |
|---|---|
| Age, y | |
| Mean | 75 |
| Median (range) | 75 (72-81) |
| Not reported | 1 |
| Sex | |
| Female | 1 |
| Male | 7 |
| Country | |
| United States | 8 |
| Year of event | |
| 2020 | 8 |
| Reported indication for use | |
| Urothelial cancer | 7 |
| Not reported | 1 |
| Time to onset, d | |
| Mean | 13 |
| Median (range) | 11 (9-21) |
| Not reported | 1 |
| No. of enfortumab vedotin doses received prior to SJS/TEN onset | |
| 2 | 6 |
| 3 | 1 |
| Not reported | 1 |
| Relevant diagnostic informationa | |
| Positive skin biopsy result | 5 |
| Diagnosed by a dermatologist | 4 |
| Admission to burn unit/ICU | 5 |
| Treatment of serious skin reactionb | |
| Corticosteroids | 7 |
| Etanercept | 1 |
| IVIG | 1 |
| Unspecified topical agents | 1 |
| Concomitant antineoplastic therapies | |
| Pembrolizumab/carboplatin | 1 |
| None | 6 |
| Not reported | 1 |
Abbreviations: ICU, intensive care unit; IVIG, intravenous immunoglobulin; SJS, Stevens-Johnson Syndrome; TEN, toxic epidermal necrolysis.
a
More than 1 method of diagnostic confirmation may have been reported per case.
b
More than 1 treatment may have been reported per case.